REALITI-A Study: Real-World Oral Corticosteroid-Sparing Effect of Mepolizumab in Severe Asthma-Reference-Cited by-同舟云学术

REALITI-A Study: Real-World Oral Corticosteroid-Sparing Effect of Mepolizumab in Severe Asthma

Published:2022-10 Issue:10 Volume:10 Page:2646-2656
ISSN:2213-2198
Container-title:The Journal of Allergy and Clinical Immunology: In Practice
language:en
Short-container-title:The Journal of Allergy and Clinical Immunology: In Practice

Author:

Pilette Charles,Canonica Giorgio Walter,Chaudhuri Rekha,Chupp Geoffrey,Lee F. Eun-Hyung,Lee Jason Kihyuk,Almonacid Carlos,Welte Tobias,Alfonso-Cristancho Rafael,Jakes Rupert W.,Maxwell Aoife,Price Robert G.,Howarth Peter

Publisher

Elsevier BV

Subject

Immunology and Allergy

Reference44 articles.

1. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma;Chung;Eur Respir J,2014

2. The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry;O'Neill;Thorax,2015

3. The Severe Asthma Network in Italy: findings and perspectives;Heffler;J Allergy Clin Immunol Pract,2019

4. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis;Harrison;Eur Respir J,2020

5. Real-world effectiveness of mepolizumab in patients with severe asthma: an examination of exacerbations and costs;Llanos;J Asthma Allergy,2020

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Effectiveness of Mepolizumab in Severe Asthma: Results from the Multi-country, Self-controlled Nucala Effectiveness Study (NEST);Advances in Therapy;2024-08-31

2. Long-term effects of mepolizumab in patients with severe eosinophilic asthma: a 6-year real-life experience;Frontiers in Pharmacology;2024-08-08

3. Therapeutic relevance of eosinophilic inflammation and airway viral interactions in severe asthma;Allergy;2024-08

4. Contemporary Concise Review 2023: Asthma;Respirology;2024-06-28

5. Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan;Drugs;2024-06